rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RANI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates
      Nov 9Investing.comRANI
      Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
      Oct 22Yahoo FinanceRANI
      Rani Therapeutics at Chardan healthcare conference: platform gains traction
      Oct 20Investing.comRANI
      Rani Therapeutics to Participate in the Chardan Healthcare Conference
      Oct 13Yahoo FinanceRANI
      H.C. Wainwright reiterates Rani Therapeutics stock rating on FDA program acceptance
      Oct 6Investing.comRANI
      Rani Therapeutics’ pill platform accepted into FDA program
      Oct 5Investing.comRANI
      Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

      ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule™ platform technology has been accepted into the U.S. Food and Drug Administration (FDA) Emerging Technology Program (ETP). The FDA’s Emerging Technology Program, ad

      Oct 5Yahoo FinanceRANI
      H.C. Wainwright Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)

      Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailRANI
      Rani Therapeutics at H.C. Wainwright: oral biologics gain traction
      Sep 14Investing.comRANI
      Rani Therapeutics to Participate in Upcoming September Conferences

      SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences. 10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital MarketsDate: Thursday, September 10, 2026 Format: 1x1 MeetingsLocation: New York, NY H.C. Wainwright 28th Annual Global Investment C

      Sep 8Yahoo FinanceRANI
      H.C. Wainwright reiterates Rani Therapeutics stock rating at buy
      Aug 21Investing.comRANI

      This is the newest page. Registered accounts read further back.